版本:
中国

BRIEF-Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

April 12 Neuralstem Inc

* Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

* Neuralstem - New cohort of four patients will be added to ongoing phase 1 human clinical trial for NSI-566 spinal cord-derived neural stem cells

* Neuralstem - Amended protocol was approved by U.S. Food and Drug Administration, institutional review board at study site, University of California San Diego Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐